刚地弓形虫病多表位疫苗的研究进展  

Research advances of multi-epitope vaccine candidates against toxoplasmosis

作　　者：李润花[1] 殷国荣[2] LI Run-hua;YIN Guo-rong(Department of Biology,Taiyuan Normal University,Jinzhong 030619,China;Institute of Medical Parasitology,Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]太原师范学院生物系,晋中030619 [2]山西医科大学医学寄生虫学研究所,太原030001

出　　处：《中国寄生虫学与寄生虫病杂志》2022年第5期661-667,672,共8页Chinese Journal of Parasitology and Parasitic Diseases

基　　金：国家自然科学基金(81071374)。

摘　　要：刚地弓形虫可感染几乎所有温血动物,引起人兽共患弓形虫病。尽管弓形虫病疫苗的研发已取得很大进展,但目前仍无预防人类弓形虫病的疫苗。研究发现,只用一种或几种候选抗原仅能诱导对弓形虫的部分保护性免疫,这限制了它们的应用。因此,利用速殖子、缓殖子和子孢子的多种抗原表位,开发由寄生虫生活史各个阶段组成的多价疫苗可能是完全保护性免疫所必需的。选用寄生虫生活史不同阶段的多表位组合已成为获得安全和有效疫苗的最佳策略。基于多表位的疫苗因其诱导保护性免疫应答能力强而作为新的疫苗候选物受到关注。本文概述了多表位疫苗的免疫学基础、设计与构建策略,总结了弓形虫多表位疫苗的最新研究进展,并展望了多表位疫苗作为一种新的疫苗开发和评估策略的应用前景。Toxoplasma gondii infects almost all warm-blooded animals causing toxoplasmosis in humans and animals. Despite the significant progress in the recent efforts toward developing an effective vaccine against toxoplasmosis, no human vaccines are available to prevent this disease. However, vaccines based on a single or a few antigen candidates was only able to elicit partial protective immunity against T. gondii infection. Therefore,developing a polyvalent vaccine consisting of antigens from all stages of the parasite life cycle, including tachyzoites,bradyzoites, and sporozoites, is likely to be essential for sterile immunity. The combination of multi-epitopes from antigens of different stages of the parasite life cycle has become an promising strategy for building a potent, safe,and effective vaccine. Epitope-based vaccines have gained attention as novel vaccine candidates due to their ability of inducing protective immune responses. In this review, we have summarized the immunological basis, design, and construction strategy of epitope vaccines. We have reviewed the latest research advances of T. gondii epitope vaccines, and the application prospect of epitope vaccines as a new vaccine development and evaluation strategy.

关 键 词：弓形虫病 B细胞和T细胞表位 多表位疫苗 抗原表位 

分 类 号：R531.8[医药卫生—内科学]